26 April 2023 
EMA/CHMP/177745/2023 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Orkambi 
lumacaftor / ivacaftor 
On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Orkambi. The marketing authorisation holder for this medicinal product is Vertex Pharmaceuticals 
(Ireland) Limited. 
The CHMP recommended the approval of a new presentation of Orkambi (75mg/94mg granules in sachet) 
and an extension to the existing indication to allow use in children from 1 year of age.  
For information, the full indication for Orkambi will be as follows2: 
Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in patients aged 1 2 
years and older who are homozygous for the F508del mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene (see sections 4.2, 4.4, and 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
